Lafaine Grant, MD
Gastroenterology · Dallas, TXNPI 1306049606
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,384 of the $1,466 with a category attached, or 94.5%. Novo Nordisk AS accounts for 94.5% of it on its own, with 3 other manufacturers making up the rest. That places this record below the midpoint for gastroenterology clinicians in TX, where the typical reported total is $3,104.
Across 6 payments — averaging $244.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$1K
- Boston Scientific$34
- GSK$27
- Orphalan Inc$21
Across 50 payments — averaging $5026.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$175K
- Gilead$59K
- Bristol Myers Squibb$18K
- E.r. Squibb & Sons, L.L.C.$355
What the payments were for
- Travel & lodging$1,38494%
- Food & beverage$816%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 3 | $1,384 |
| Boston Scientific | 1 | $34 |
| GSK | 1 | $27 |
| Orphalan Inc | 1 | $21 |
How this compares
$1,466 in reported general payments places this provider in the 30th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 33 | $104,967 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $16,141 |
| Tacrolimus | 122 | $13,557 |
| Ursodiol | 110 | $13,423 |
| Entecavir | 21 | $4,285 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 32 | $2,061 |
| Lactulose | 44 | $1,673 |
| ConstuloseLactulose | 18 | $1,136 |
| Azathioprine | 16 | $1,009 |
| Spironolactone | 29 | $694 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 31 | $481 |
| Carvedilol | 40 | $472 |
| Esomeprazole Magnesium | 14 | $373 |
| Fludrocortisone Acetate | 28 | $338 |
| Pantoprazole Sodium | 43 | $308 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Dallas
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Parvez MantryDallas$958K
- Jay HortonDallas$326K
- Jacqueline O LearyDallas$157K
- Sami ArslanlarDallas$142K
- Amit DesaiDallas$71K
- Byron CryerDallas$68K
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.